Promising new treatment for aggressive kidney cancer

June 05, 2004

New Orleans, June 5, 2004 - A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers. The study's lead investigator, Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC) reported the results of a Phase II study today at the American Society for Clinical Oncology annual meeting.

"This early study of SU11248 in the treatment for renal cancer has shown more activity as a single agent then any other drug I've studied in the past 15 years," said Dr. Motzer. "While further research needs to be done to confirm these findings, I am very encouraged by this type of significant activity so early on, in treating such an aggressive disease," he added.

The novel agent, SU11248 works through simultaneously blocking multiple tumor growth factor receptors known as tyrosine kinases. These receptors are thought to be responsible for cancer growth and metastases. Through targeting multiple receptors --vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and others -- SU11248 cuts off the blood supply of the cancer while at the same time destroying cellular reproduction.

Renal cell cancer is diagnosed in approximately 30,000 people per year and has a five-year survival rate of about 55 percent. The current standard treatment for metastatic renal cell cancer is interleukin-2 and interferon-alpha, but only 15 percent of treated patients have a response.

In the current study, 63 patients with metastatic (advanced) renal carcinoma whose cancer had failed to respond to standard therapy received SU11248. Twenty-one of them (33 percent) showed a partial response to the drug, another 40 percent had disease stabilization. Six months later, the SU11248 response has persisted in some patients, and 14 of the responders continue on treatment with an ongoing partial response. The drug is taken orally and it was generally well tolerated, with patients experiencing mild to moderate side effects.

This was a multi-center study that included investigators from several US centers. The study is sponsored by Pfizer Pharmaceuticals.

Dr. Motzer is also the lead investigator on a pivotal Phase III trial for SU11248 as the second line of therapy. Additionally, there will be another Phase III trial comparing SU11248 to the standard therapy of interferon. This trial is expected to start accrual in the next few months.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to

Memorial Sloan Kettering Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to